Creating a Safe, Reliable Pharmaceutical Supply Chain
Tags: December 2022, Pharmaceutical Logistics The Challenge The Solution No Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreTags: December 2022, Pharmaceutical Logistics The Challenge The Solution No Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreNew annual research conducted by Ipsos for the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), shows that the research-based pharmaceutical industry has garnered a positive reputation, with its pandemic response and the impact of its innovations seen as key…
Read More(PRNewsfoto/Antengene Corporation Limited)Before joining Antengene, Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or “Hengrui Pharma”), including Vice President, Head of Clinical Development – Oncology, Corporate Vice President and Chief Medical Officer for
Read MoreDrug Discovery Outsourcing Market Size By Drug Type (Small and Large Molecules), By Therapeutic Area (Respiratory System, Oncology, Immunomodulation, and Others), By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, and Others), Regions,…
Read MoreJRS Pharma is already the world’s largest producer of cellulosic products for the pharmaceutical industry, and the company’s recently announced $18 million expansion of its southwest Cedar Rapids manufacturing operations brings nearly half of the company’s pharmacellulosic operations to the…
Read MoreWhat Are The Benefits of Investing in Pharmaceutical Stocks? The 7 Best Pharmaceutical Stocks To Invest In Now For A Profitable 2022 Johnson & Johnson Pfizer Merck Amgen Biogen Gilead Sciences AbbVie No…
Read MoreNo Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreScientists have created a much faster way to make certain complex molecules, which are widely used by pharmaceuticals for antibiotics and anti-fungal No Byline Policy Editorial Guidelines Corrections Policy Source
Read MoreKatie Laughlin is a business and offering development professional with 20 years of experience in pharma, medical device, and CRO organisations with a focus in clinical trials and commercial information She works with a consultative and strategic approach, focusing…
Read MoreIn September, Centers for Medicare and Medicaid Services will list the 10 Part D drugs whose negotiated prices will take effect in Negotiations begin in October and end in August 2024, according to Kaiser Family Foundation’s Another round…
Read More